Prothena
Prothena Corporation specializes in protein dysregulation, developing investigational therapies for neurodegenerative and rare diseases, and collaborates with leading pharmaceutical companies.
Company History
Prothena was founded in December 2012 after separating from Elan Corporation, plc. The company began trading on the Nasdaq Global Market under the symbol 'PRTA'. Since its founding, Prothena has specialized in protein dysregulation and developed a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases.
Products and Clinical Pipeline
Prothena develops therapies targeting neurological dysfunction and the biology of misfolded proteins. The company's clinical pipeline includes birtamimab for AL amyloidosis and prasinezumab for Parkinson's disease. Prothena also has several programs aimed at addressing Alzheimer's disease, including PRX012. The focus of these therapies is to address diseases linked to protein misfolding and aggregation.
Collaborations and Partnerships
Prothena collaborates with major pharmaceutical companies like Roche and Novo Nordisk to advance its clinical programs. The company actively engages in partnerships across the biotechnology and pharmaceutical industry to accelerate the development of new medicines. These collaborations are pivotal in enhancing Prothena's ability to innovate and bring new therapies to market.
Sector and Specialization
Prothena operates within the biotechnology sector, specializing in protein dysregulation. The company's focus is on developing therapies for neurodegenerative and rare peripheral amyloid diseases. By targeting neurological dysfunction and the underlying biology of misfolded proteins, Prothena aims to address complex diseases such as Alzheimer's, Parkinson's, and various forms of amyloidosis.
Mission and Commitment
Prothena is committed to quality and innovation in developing therapies that improve the lives of patients with neurodegenerative and rare diseases. The company's mission is to translate scientific research into treatment solutions that can make a meaningful difference in the lives of patients affected by these challenging conditions.